JOURNAL OF MEDICINAL CHEMISTRY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-11-16 ms7000000149561313

第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中

141 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-09-26 122f7df6m01(暂无昵称)

审稿速度:1.0
偏重的研究方向：药物化学
经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。

145 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-12-28 学医的彭于晏

Graphicalabstract是什么？

123 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-12-27 Mia

投稿中一定要有Graphicalabstract么？

127 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-07-05 cindichaw

以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。

154 0

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-06-01 波0

审稿速度:2.0 | 投稿命中率:25.0
经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收

159 0

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2021-03-13 Y25341e2m)

投了篇，一审都五周了还没消息，一般不是三四周吗

168 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2020-07-02 146bff12m25暂无昵称

审稿速度:1.0
经验分享：一审三周，大修一个半月，二审三周接收

233 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2019-12-28 mgp299_66108732

已经1区了

267 0

[GetPortalCommentsPageByObjectIdResponse(id=1070675, encodeId=435f10e0675d7, content=第一次投JMC，一审五个审稿人，一小修、三大修、一拒稿，编辑给了大修。两个月俢回，三周收到二修消息，三个审稿人没提什么意见，一接收、二小修，第二天返回，等待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=141, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe025646832, createdName=ms7000000149561313, createdTime=Tue Nov 16 09:19:40 CST 2021, time=2021-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055009, encodeId=318e105500966, content=审稿速度:1.0 偏重的研究方向：药物化学 经验分享：投了两次，第一次秒拒；第二次加了些数据，当天晚上主编 Lindsley 就送审了，很快3周后有了消息，三个审稿人，一个大修两个小修，给了2个月修改。一周其实我就改好了，拖了一个月递交。现在等待消息中。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=145, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=8e0a2372682, createdName=122f7df6m01(暂无昵称), createdTime=Sun Sep 26 15:49:25 CST 2021, time=2021-09-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093621, encodeId=87f51093621ab, content=Graphicalabstract是什么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=123, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:49 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1093622, encodeId=9dd1109362246, content=投稿中一定要有Graphicalabstract么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=127, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220301/3a52d3952dde49019f1e000bb5c41d1c/0a0eb7959bb14fcd87745f869bee3c33.jpg, createdBy=46f32239729, createdName=Mia, createdTime=Mon Dec 27 14:52:49 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996585, encodeId=ae4599658534, content=以前通讯了一篇，评委友好。化学与生物医学结合好，可以发表。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=4fed1686029, createdName=cindichaw, createdTime=Mon Jul 05 22:09:55 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=970184, encodeId=87199e01842e, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：一审6周，三个审稿人大修，一个拒稿，编辑给了两个月的修回时间二审7周，二个审稿人同意接收，一个仍然拒稿，编辑给了两个月修回时间三审3周，主编没送外审，亲自给了修改意见，给了一个月修回时间四审5天接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0f3c1739990, createdName=波0, createdTime=Tue Jun 01 22:50:54 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947803, encodeId=7a2c94e80334, content=投了篇，一审都五周了还没消息，一般不是三四周吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Fvoq53Fib5icNdYxvW8TMtzULJblc3CRxuYotjtu5AMoLibRhN1wvFzFFNApDg6eoicxk2VlRIhZpWUjXjsYz1HASg/132, createdBy=e9502547347, createdName=Y25341e2m), createdTime=Sat Mar 13 08:22:35 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=800960, encodeId=39dc80096083, content=审稿速度:1.0 经验分享：一审三周，大修一个半月，二审三周接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=233, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=75f15163445, createdName=146bff12m25暂无昵称, createdTime=Thu Jul 02 20:46:18 CST 2020, time=2020-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=582283, encodeId=2f47582283ac, content=已经1区了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=267, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44f45255172, createdName=mgp299_66108732, createdTime=Sat Dec 28 10:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=577495, encodeId=458d5e749517, content=确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表: 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, beContent=focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!, objectType=tool_impact_factor, channel=null, level=null, likeNumber=289, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85305202900, createdName=14742525m29暂无昵称, createdTime=Tue Oct 08 00:00:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]

2019-10-08 14742525m29暂无昵称

确实是这样药化里的顶级期刊了focuschem 2018-05-13 发表::
SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!focuschem 2018-05-13 00:00:00 发表:
这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!

focuschem 2018-05-13 发表:: SCI(2016)：6.259 SCI(2015)：5.589 SCI(2014)：5.447 这个期刊的地位完全可以称得上大类一区.为啥被弄到医药二区?非常不公平!jmc的地位相当于有机方法学中的jacs!而且附带的价值远超jacs.angew!

289 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务